Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ)
Chongqing, CN
Chongqing Pharscin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the research, development, manufacturing, and distribution of medicines. Its product portfolio encompasses a broad spectrum of pharmaceutical formulations, such as tablets, powders, granules, hard and soft capsules, alongside various injectables including powder, freeze-dried powder, and small volume injections. The company also specializes in active pharmaceutical ingredient (API) synthesis. This diverse range of products targets critical therapeutic areas, including the central nervous system (CNS), digestive health, otolaryngology, oncology, as well as cardiovascular and cerebrovascular conditions. Established in 1996, the company maintains its headquarters in Chongqing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.39% | -1.82% | -10.98% | -16.72% | -23.46% | -16.27% | -34.04% | -22.84% | -4.98% | +90.18% | +90.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.8% Q1'26: -12.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-11.1% Q1'26: -18.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.0% Q1'26: +9.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+9.4% Q1'26: +14.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+5.1% Q1'26: +8.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.1% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.02× ★ Q1'26: 0.34× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 184.1K | 0.06% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 56.9K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 49.1K | 0.29% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 5.3K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 12.0K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 591.7K | 0.06% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 23.2K | 0.28% |
| 8 | Vanguard ESG International Stock ETF VSGX | 0.00% | 8.8K | 0.10% |
| 9 | Vanguard Total International Stock ETF VXUS | 0.00% | 708.3K | 0.05% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 950.96 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ge Lei | Securities Affairs Representative | — | — |
| Jie Huang | Deputy General Manager | — | male |
| Lie Chun Chen | Chief Technology Officer | — | male |
| Xiaoyan Peng | Accounting Supervisor & Chief Financial Officer | — | female |
| Xiaoying Liu | Chief Executive Officer, GM & Director | — | female |
| Xu Jun | Securities Affairs Representative | — | — |
| Xue Dan You | Deputy GM, Secretary of the Board & Non-Independent Director | — | female |
| Ying Wang | Head of Phramaceutical Sales, Deputy GM & Director | — | female |
| Yong Lu Hang | Chief Operating Officer & Deputy GM | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002907.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
